When does the voclosporin (Lupkynis) patent expire in Europe?
Patent expiry dates for voclosporin in Europe depend on which protection you mean: the original patents’ end dates, any supplementary protection certificates (SPCs) granted by specific EU countries, and later “pipeline” patents covering new formulations, combinations, or manufacturing improvements. Without the exact patent family number or the specific country (e.g., UK, Germany, France), there is no single definitive “Europe expiry” date.
Which countries count as “Europe” for patent expiry?
In practice, users usually mean one of these:
- EU member states (where EU SPC rules can extend patent protection for eligible products), or
- the UK (which applies its own UK patent/SPC framework even after Brexit).
The “expiry” date you see online can shift because of these jurisdiction differences, plus whether an SPC exists for that jurisdiction.
How can you find the exact expiry date you need (without guessing)?
To get a reliable voclosporin expiry date for a specific market, you typically:
- Identify the relevant patent family for voclosporin (often multiple patents per product).
- Check whether an SPC was granted in the target country.
- Use the country-specific registry data to see the actual end date of the granted rights.
If you tell me the country (or whether you mean EU-wide vs UK) and what you mean by “expiry” (basic patent vs SPC vs exclusivity), I can narrow the answer to the right protection type.
What if the basic patent expired earlier than market exclusivity?
Even if the underlying patent ends, market exclusivity can still be extended by:
- SPC protection (if granted), and/or
- later patents covering incremental but protected aspects of the product.
That’s why you may see different dates labeled as “patent expiry,” “SPC expiry,” and “regulatory exclusivity.”
What’s the likely next step after expiry?
After the last relevant patent/SPC protection ends in a given country, competitors can potentially pursue:
- generic or biosimilar-style developments where legally allowed (voclosporin is a small molecule, so “generic” is the key pathway), and/or
- label/legal challenge routes tied to the drug’s market authorization status.
Actual launch timing still depends on national patent/SPC status, any litigation/settlement, and regulatory readiness.
Quick clarifying question
Which do you mean by “Europe” and “expiry”?
1) EU member states only, or include the UK?
2) Do you want the end of the core patent, the end of an SPC, or “earliest possible generic entry” in Europe?
3) If you know it, what is the voclosporin patent family number or the country you care about most?
Sources: none provided in the prompt.